Lipocine to Present at H.C. Wainwright Conference Sept 8-10, 2025

Lipocine Inc.

Company management will present and hold 1x1 meetings at H.C. Wainwright 27th Annual Global Investment Conference in New York.
Conference runs September 8-10, 2025; presentation available from 7:00 a.m. EDT on Sept 5.
Lipocine's pipeline includes LPCN 1154 (postpartum depression), LPCN 2101 (epilepsy), LPCN 2203 (essential tremor), and others.
TLANDO (testosterone undecanoate) is FDA-approved for hypogonadism; company exploring partnerships for several candidates.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.